Method for Identification of Relapse Risk and Treatment in Patients with Colorectal Cancer

Summary of the technology

- Accurately prediction of the risk of colorectal cancer recurrence by analyzing six microRNAs (miRNAs) in patient samples.
- The miRNA panel provides distinctive signatures for identifying the source of metastases and correlates with recurrence-free survival.
- The method enables personalized treatment by administering therapeutic agents based on the determined risk of recurrence.

Georgetown University

OVERVIEW

Colorectal cancer (CRC) is a major cause of cancer mortality worldwide. Georgetown researchers developed A Method of predicting recurrence of colorectal cancer by measuring a combination of six microRNAs (miRNAs) taken from a patient samples, where evaluating the hierarchical clustering of the six circulating miRNAs indicates the risk of cancer recurrence. Thismethod offers a solution for predicting the risk of CRC recurrence by measuring six miRNAs in patient samples. The hierarchical clustering of these miRNAs indicates the probability of cancer recurrence, providing valuable information for personalized treatment. Additionally, the miRNA panel helps identify the organ source of metastases and correlates with recurrence-free survival. By administering therapeutic agents based on the determined risk, this method improves treatment outcomes for patients with CRC.

BACKGROUND

Colorectal cancer is a significant public health problem, causing a substantial number of cancer-related deaths globally. Existing diagnostic methods based on biomarkers are limited, and there is a need for approaches that can identify patients at high risk of recurrence. This method addresses this need by utilizing a combination of miRNAs, which have prognostic potential in colon cancer. By analyzing the expression levels of specific miRNAs in tissues, it accurately predicts recurrence risk and allows for personalized treatment decisions.

Benefit

  • Utilizes easily accessible bio-specimen (blood) for analysis.
  • Employs a standard six-member miRNA panel for conclusive diagnosis and risk assessment.
  • Enables high throughput screening, allowing for efficient analysis of multiple patient samples.

Market Application

  • Evaluation of colon cancer recurrence risk.
  • Companion diagnostic tool for patients with early-stage colon cancer.

Publications

US PatentUS10351913B2

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Heart and blood circulation illnesses
  • Diagnostic
  • cancer

About Georgetown University

Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.

Georgetown University

Never miss an update from Georgetown University

Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide

Georgetown University

Send a request for information
to Georgetown University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support